Supernus Pharmaceuticals Inc (SUPN) VP Sells $630,600.00 in Stock

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total value of $630,600.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at approximately $1,023,421.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Victor Vaughn also recently made the following trade(s):

  • On Tuesday, January 2nd, Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $40.11, for a total value of $2,206,050.00.

Supernus Pharmaceuticals Inc (NASDAQ SUPN) traded up $1.75 during midday trading on Tuesday, reaching $42.70. The company’s stock had a trading volume of 744,574 shares, compared to its average volume of 435,945. Supernus Pharmaceuticals Inc has a 52 week low of $23.10 and a 52 week high of $50.04. The firm has a market cap of $2,190.00, a PE ratio of 38.82 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The business had revenue of $80.40 million for the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s quarterly revenue was up 41.5% on a year-over-year basis. equities research analysts forecast that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.

Several research firms have issued reports on SUPN. Piper Jaffray Companies reiterated a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 20th. Cowen reiterated a “buy” rating and set a $50.00 target price on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Finally, B. Riley reiterated a “buy” rating and set a $50.00 target price (down previously from $53.00) on shares of Supernus Pharmaceuticals in a research report on Monday, November 6th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $50.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in shares of Supernus Pharmaceuticals by 0.5% in the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after acquiring an additional 31,331 shares during the period. Vanguard Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after acquiring an additional 984,200 shares during the period. State Street Corp grew its holdings in shares of Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after acquiring an additional 42,165 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Supernus Pharmaceuticals by 10.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after acquiring an additional 122,042 shares during the period. Finally, Neumeier Poma Investment Counsel LLC grew its holdings in shares of Supernus Pharmaceuticals by 1.6% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after acquiring an additional 14,430 shares during the period. Institutional investors and hedge funds own 98.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Supernus Pharmaceuticals Inc (SUPN) VP Sells $630,600.00 in Stock” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/10/supernus-pharmaceuticals-inc-supn-vp-sells-630600-00-in-stock.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply